InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with mRNA ...

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing ...

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study in older adults.